Michael T. Flavin

Biography

    Dr. Michael Flavin is Chief Executive Officer of Shamrock Structures and a Managing Director of Flavin Ventures, LLC—the group that founded and launched Shamrock Structures. He was the founder, Chief Executive Officer, and Chairman of MediChem Life Sciences, Inc. (NASDAQ:MCLS). Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the successful completion of MediChem's $35M private placement in 1999, the acquisition and integration of ThermoGen and Emerald Biostructures and MediChem's October, 2000 $54M IPO. He oversaw formation of the AXAS subsidiary and contract with the U.S. Department of Energy and management of the COMCAT beam line at the Advanced Photon Source at Argonne National Laboratory. MediChem was acquired in 2002 by deCODE genetics (NASDAQ:DCGN) for $83M. Dr. Flavin received a Bachelor of Science in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago, and completed a postdoctoral fellowship at Harvard University. Prior to founding MediChem, Dr. Flavin worked as a Senior Research Associate for Baxter International.  

Research Interest

 Clinical Research & Bioethics